Marburg virus (MARV) and Ebola virus, members of the family Filoviridae, cause lethal haemorrhagic fever in humans and non-human primates. Although the outbreaks are concentrated mainly in Central Africa, these viruses are potential agents of imported infectious diseases and bioterrorism in non-African countries. Recent studies demonstrated that non-human primates passively immunized with virus-specific antibodies were successfully protected against fatal filovirus infection, highlighting the important role of antibodies in protective immunity for this disease. However, the mechanisms underlying potential evasion from antibody mediated immune pressure are not well understood. To analyse possible mutations involved in immune evasion in the MARV envelope glycoprotein (GP) which is the major target of protective antibodies, we selected escape mutants of recombinant vesicular stomatitis virus (rVSV) expressing MARV GP (rVSVΔG/MARVGP) by using two GP-specific mAbs, AGP127-8 and MGP72-17, which have been previously shown to inhibit MARV budding. Interestingly, several rVSVΔG/MARVGP variants escaping from the mAb pressure-acquired amino acid substitutions in the furin-cleavage site rather than in the mAb-specific epitopes, suggesting that these epitopes are recessed, not exposed on the uncleaved GP molecule, and therefore inaccessible to the mAbs. More surprisingly, some variants escaping mAb MGP72-17 lacked a large proportion of the mucin-like region of GP, indicating that these mutants efficiently escaped the selective pressure by deleting the mucin-like region including the mAb-specific epitope. Our data demonstrate that MARV GP possesses the potential to evade antibody mediated immune pressure due to extraordinary structural flexibility and variability.
AmmanB. R., CarrollS. A., ReedZ. D., SealyT. K., BalinandiS., SwanepoelR., KempA., EricksonB. R., ComerJ. A.other authors2012; Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog 8:e1002877 [View Article][PubMed]
BrindleyM. A., HughesL., RuizA., McCrayP. B.Jr, SanchezA., SandersD. A., MauryW.2007; Ebola virus glycoprotein 1: identification of residues important for binding and postbinding events. J Virol 81:7702–7709 [View Article][PubMed]
DyeJ. M., HerbertA. S., KuehneA. I., BarthJ. F., MuhammadM. A., ZakS. E., OrtizR. A., PrugarL. I., PrattW. D.2012; Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 109:5034–5039 [View Article][PubMed]
FeldmannH., WillC., SchikoreM., SlenczkaW., KlenkH. D.1991; Glycosylation and oligomerization of the spike protein of Marburg virus. Virology 182:353–356 [View Article][PubMed]
FeldmannH., NicholS. T., KlenkH. D., PetersC. J., SanchezA.1994; Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199:469–473 [View Article][PubMed]
García-BarrenoB., PortelaA., DelgadoT., LópezJ. A., MeleroJ. A.1990; Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. EMBO J 9:4181–4187[PubMed]
HangartnerL., ZinkernagelR. M., HengartnerH.2006; Antiviral antibody responses: the two extremes of a wide spectrum. Nat Rev Immunol 6:231–243 [View Article][PubMed]
HollandJ. J., DomingoE., de la TorreJ. C., SteinhauerD. A.1990; Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol 64:3960–3962[PubMed]
LeeJ. E., SaphireE. O.2009; Neutralizing Ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it. Curr Opin Struct Biol 19:408–417 [View Article][PubMed]
LeeJ. E., FuscoM. L., HessellA. J., OswaldW. B., BurtonD. R., SaphireE. O.2008; Structure of the Ebola virus glycoprotein bound to a human survivor antibody. Nature 454:177–182 [View Article][PubMed]
MarziA., YoshidaR., MiyamotoH., IshijimaM., SuzukiY., HiguchiM., MatsuyamaY., IgarashiM., NakayamaE.other authors2012; Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE 7:e36192 [View Article][PubMed]
NeumannG., FeldmannH., WatanabeS., LukashevichI., KawaokaY.2002; Reverse genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein is not essential for replication in cell culture. J Virol 76:406–410 [View Article][PubMed]
NeumannG., GeisbertT. W., EbiharaH., GeisbertJ. B., Daddario-DiCaprioK. M., FeldmannH., KawaokaY.2007; Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. J Virol 81:2995–2998 [View Article][PubMed]
ReynardO., BorowiakM., VolchkovaV. A., DelpeutS., MateoM., VolchkovV. E.2009; Ebolavirus glycoprotein GP masks both its own epitopes and the presence of cellular surface proteins. J Virol 83:9596–9601 [View Article][PubMed]
SanchezA., GeisbertT. W., FeldmannH.2007; Filoviridae: Marburg and Ebola viruses. In Fields Virology, 5th edn. pp. 1409–1448 Edited by KnipeD. M., HowleyP. M. Philadelphia, PA: Lippincott Williams & Wilkins;
ShedlockD. J., BaileyM. A., PopernackP. M., CunninghamJ. M., BurtonD. R., SullivanN. J.2010; Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 401:228–235 [View Article][PubMed]
SimmonsG., Wool-LewisR. J., BaribaudF., NetterR. C., BatesP.2002; Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J Virol 76:2518–2528 [View Article][PubMed]
TakadaA., RobisonC., GotoH., SanchezA., MurtiK. G., WhittM. A., KawaokaY.1997; A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A 94:14764–14769 [View Article][PubMed]
TakadaA., FeldmannH., StroeherU., BrayM., WatanabeS., ItoH., McGregorM., KawaokaY.2003; Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol 77:1069–1074 [View Article][PubMed]
TownerJ. S., AmmanB. R., SealyT. K., CarrollS. A., ComerJ. A., KempA., SwanepoelR., PaddockC. D., BalinandiS.other authors2009; Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 5:e1000536 [View Article][PubMed]
Wool-LewisR. J., BatesP.1998; Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J Virol 72:3155–3160[PubMed]
Wool-LewisR. J., BatesP.1999; Endoproteolytic processing of the Ebola virus envelope glycoprotein: cleavage is not required for function. J Virol 73:1419–1426[PubMed]